Dr. Saw Discusses Study of Vitamin D in Melanoma

Robyn Saw, FRACS, MS, MBBS
Published: Monday, Oct 30, 2017



Robyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.

This phase II study aims to find an alternative therapy option for patients with melanoma who are at high risk for recurrence. Currently, the only option for these patients is surgery.

In the study, patients received adjuvant therapy with high-dose vitamin D following primary treatment. Vitamin D has shown potential to delay recurrence and improve prognosis. Currently, there is no effective nontoxic adjuvant therapy for this population.
 
SELECTED
LANGUAGE


Robyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.

This phase II study aims to find an alternative therapy option for patients with melanoma who are at high risk for recurrence. Currently, the only option for these patients is surgery.

In the study, patients received adjuvant therapy with high-dose vitamin D following primary treatment. Vitamin D has shown potential to delay recurrence and improve prognosis. Currently, there is no effective nontoxic adjuvant therapy for this population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x